JP2022501436A5 - - Google Patents

Info

Publication number
JP2022501436A5
JP2022501436A5 JP2021539501A JP2021539501A JP2022501436A5 JP 2022501436 A5 JP2022501436 A5 JP 2022501436A5 JP 2021539501 A JP2021539501 A JP 2021539501A JP 2021539501 A JP2021539501 A JP 2021539501A JP 2022501436 A5 JP2022501436 A5 JP 2022501436A5
Authority
JP
Japan
Prior art keywords
substituted
heterocycle
alkyl
aryl
cycloalkyl
Prior art date
Application number
JP2021539501A
Other languages
English (en)
Japanese (ja)
Other versions
JP7557788B2 (ja
JPWO2020061232A5 (https=
JP2022501436A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051790 external-priority patent/WO2020061232A1/en
Publication of JP2022501436A publication Critical patent/JP2022501436A/ja
Publication of JPWO2020061232A5 publication Critical patent/JPWO2020061232A5/ja
Publication of JP2022501436A5 publication Critical patent/JP2022501436A5/ja
Priority to JP2024152701A priority Critical patent/JP2024163257A/ja
Application granted granted Critical
Publication of JP7557788B2 publication Critical patent/JP7557788B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539501A 2018-09-18 2019-09-18 非アルコール性脂肪性肝疾患に対する処置 Active JP7557788B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024152701A JP2024163257A (ja) 2018-09-18 2024-09-04 非アルコール性脂肪性肝疾患に対する処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732644P 2018-09-18 2018-09-18
US62/732,644 2018-09-18
PCT/US2019/051790 WO2020061232A1 (en) 2018-09-18 2019-09-18 Treatment for non-alcoholic fatty liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024152701A Division JP2024163257A (ja) 2018-09-18 2024-09-04 非アルコール性脂肪性肝疾患に対する処置

Publications (4)

Publication Number Publication Date
JP2022501436A JP2022501436A (ja) 2022-01-06
JPWO2020061232A5 JPWO2020061232A5 (https=) 2022-10-04
JP2022501436A5 true JP2022501436A5 (https=) 2022-10-04
JP7557788B2 JP7557788B2 (ja) 2024-09-30

Family

ID=69888816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539501A Active JP7557788B2 (ja) 2018-09-18 2019-09-18 非アルコール性脂肪性肝疾患に対する処置
JP2024152701A Pending JP2024163257A (ja) 2018-09-18 2024-09-04 非アルコール性脂肪性肝疾患に対する処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024152701A Pending JP2024163257A (ja) 2018-09-18 2024-09-04 非アルコール性脂肪性肝疾患に対する処置

Country Status (12)

Country Link
US (2) US12318381B2 (https=)
EP (1) EP3852753A4 (https=)
JP (2) JP7557788B2 (https=)
KR (1) KR102890555B1 (https=)
CN (1) CN112955143B (https=)
AU (1) AU2019345297B2 (https=)
BR (1) BR112021005086A2 (https=)
CA (1) CA3113016A1 (https=)
MX (1) MX2021003156A (https=)
SG (1) SG11202102684VA (https=)
TW (1) TWI825177B (https=)
WO (1) WO2020061232A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392555B (es) 2016-09-07 2025-03-24 Univ Temple Composiciones y métodos para el tratamiento de resistencia a la insulina.
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
TW202206062A (zh) * 2020-04-24 2022-02-16 美國坦普大學 高等教育聯邦系統 治療非酒精性脂肪肝炎的方法
WO2022040324A1 (en) * 2020-08-18 2022-02-24 Metrea Biosciences, Inc. COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13
WO2023174543A1 (en) * 2022-03-17 2023-09-21 Siemens Industry Software GmbH Managing artifact information relating to a physical system, especially improving traceability of re-baselined engineering-related information, method and system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100977A2 (en) 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
EP3037419B1 (en) * 2007-09-06 2019-09-04 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
HK1220184A1 (zh) * 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
WO2014202528A1 (en) 2013-06-20 2014-12-24 Boehringer Ingelheim International Gmbh Olefin substituted oxindoles having ampk activity
EP2886541A1 (en) 2013-12-19 2015-06-24 Sanofi Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
RU2016128396A (ru) 2014-01-27 2018-03-02 Бостон Биомедикал, Инк. Новые способы лечения рака
US10377749B2 (en) 2015-08-10 2019-08-13 Sumitomo Dainippon Pharma Co., Ltd. Purification method for 5-(thiazol-4-yl)indolin-2-one derivative
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
AU2016348638A1 (en) 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
JP2019519573A (ja) * 2016-06-28 2019-07-11 ボストン バイオメディカル, インコーポレイテッド がんを処置するための方法
CN117224541A (zh) * 2018-09-18 2023-12-15 北京强新生物科技有限公司 肥胖症的治疗

Similar Documents

Publication Publication Date Title
JP2022501436A5 (https=)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
RU2015139590A (ru) ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ
JP2012507566A5 (https=)
JP2020521730A5 (https=)
CA2703125A1 (en) Pyrazinyl-substituted pyrrolo[2,3-b]pyridines, compositions thereof, and their use in the treatment of cancer
JP2016517417A5 (https=)
RU2019104092A (ru) Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
KR20220086628A (ko) Prmt5 저해제의 약학적 조합물
JP2019517487A5 (https=)
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
RU2018104702A (ru) Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ
KR970001322A (ko) 당뇨병 저해제로서의 치환 n-[인돌-2-카보닐]-글리신아미드 및 유도체
RU2016141647A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
IL291590B1 (en) Novel modified quinoline-8-carbonitrile compounds with androgen receptor unblocking activity and their uses
ME02906B (me) Derivati pirazolopirolidina i njihova upotreba u liječenju bolesti
JP2007519694A5 (https=)
RU2014153627A (ru) Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ
JP2019507179A5 (https=)
RU2009119181A (ru) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
RU2014141674A (ru) 3,5-диаминопиразоловые ингибиторы киназы
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
CA3127152A1 (en) Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
FI3853218T3 (fi) Somatostatiinin modulaattoreita ja niiden käyttöjä